The clinical relevance of obesity and glucagon-like peptide-1-based therapies for chronic weight management in patients treated by obstetrician-gynecologists and gynecologists: A non-systematic narrative review
Abstract
Women pre- or post-menopause and living with obesity are at an increased risk of obesity-related complications such as polycystic ovary syndrome, infertility, cardiovascular disease, and breast and uterine cancers. Previously, it has been demonstrated that a clinically meaningful weight loss of ≥5% of total body weight can have benefits for women living with gynecological conditions related to obesity and can improve the symptoms of polycystic ovary syndrome, improve fertility, and reduce the risk of gynecological and breast cancers. In this review article, we provide an overview of the impact of obesity on women's health and evaluate the current pharmacological treatment landscape for weight management, with particular emphasis on incretin-based therapies, as relevant treatment options for obstetrician-gynecologists and gynecologists treating women at an increased risk of obesity-related complications. Literature searches were conducted using PubMed to identify articles published between 2015 and 2026, with the search date range subsequently expanded to articles published within the last 30 years. English language and adult only were specified in the filters for the search criteria, as was publication type (narrative reviews, systematic reviews, and randomized controlled trials were included). Searches were also conducted without any filters. With glucagon-like peptide-1 receptor agonists established as effective weight-management tools, obstetrician-gynecologists and…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.